Answers are grounded in this paper and cite their sources.
T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) is a receptor found on a multitude of immune cells and is commonly overexpressed in patients with cancer. Due to its selective expression in immune cells and its preliminary efficacy in preclinical models, TIM-3 is a promising target as a treatment for cancer. Both monotherapy and combination regimens are being developed and are currently under investigation. This clinical review seeks to summarize and compile past, present, and future TIM-3 inhibitors in clinical trials.
No takes yet. Share an insight, caveat, or question.
Duong et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: